Genzyme severs link with SYN-X on stroke technology
This article was originally published in Clinica
Genzyme Diagnostics has modified its deal with SYN-X Pharma to commercialise a test for diagnosing, distinguishing and monitoring stroke. The two companies say that a new agreement supersedes their prior arrangements and "amicably resolves all prior disputes between them".
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.